First Case Report of Aseptic Meningitis Induced by Adalimumab Administered for Treatment of Chronic Plaque Psoriasis

Wang, Dingyuan; Chong, Wei‐Sheng; Pan, Jiun Yit; Heng, Yee Kiat

doi:10.18176/jiaci.0148

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2] Direct drug toxicity to the brain is not considered a viable mechanism due to its inability to cross the blood brain barrier. [3] Since the first report of TAAM was published in 2001, [2] several other cases have now been now published. [3,4,5] In addition, other, even less common, neurologic manifestations have been reported including: Guillain-Barre, [9] multiple sclerosis, [10] optic neuritis, [11,12] demyelinating encephalomyelitis, [13] and mononeuritis multiplex.…”

Section: Discussionmentioning

confidence: 99%

“…[3] Since the first report of TAAM was published in 2001, [2] several other cases have now been now published. [3,4,5] In addition, other, even less common, neurologic manifestations have been reported including: Guillain-Barre, [9] multiple sclerosis, [10] optic neuritis, [11,12] demyelinating encephalomyelitis, [13] and mononeuritis multiplex. [14] While most patients with TAAM had normal neurologic exams, some did have objective lower extremity weakness [9] or positive Kernig/Brudzinski signs.…”

Section: Discussionmentioning

confidence: 99%

“…[2] To date, there have been 13 published cases describing the correlation between TNFα-i and aseptic meningitis. [3,4,5] Presented is a case report on a young male recently prescribed adalimumab for Crohn's disease who developed aseptic meningitis with associated focal partial seizures.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease

Ellis¹,

Smith²,

Veach³

2019

AJMCR

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease

Ellis¹,

Smith²,

Veach³

2019

AJMCR

View full text Add to dashboard Cite

show abstract

“…OKT3 (muromonab), a murine anti‐CD3 antibody, was the first monoclonal antibody (mAb) used for therapeutic applications but also the first implicated in a drug‐induced aseptic meningitis . Chimeric mAb, such as cetuximab or infliximab , but also humanized mAb such as efalizumab and adalimumab have already been involved in DIAM. Ipilimumab (anti CTLA‐4), nivolumab, or pembrolizumab (two anti PD‐1) are immune checkpoint inhibitors (ICIs) used in metastatic melanoma and usually associated with ancillary immune‐related adverse effects (irAEs).…”

Section: Identification Of Causative Agents Involved In Diammentioning

confidence: 99%

Drug‐induced aseptic meningitis: a mini‐review

Yéléhé‐Okouma

Czmil-Garon

Pape

et al. 2018

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Aseptic meningitis associates a typical clinical picture of meningitis with the absence of bacterial or fungal material in the cerebrospinal fluid. Drug-induced aseptic meningitis (DIAM) may be due to two mechanisms: (i) a direct meningeal irritation caused by the intrathecal administration of drugs and (ii) an immunologic hypersensitivity reaction to a systemic administration. If the direct meningeal irritation allows a rather easy recognition, the immunologic hypersensitivity reaction is a source of challenging diagnostics. DIAM linked to a systemic treatment exerts typically an early onset, usually within a week. This period can be shortened to a few hours in case of drug rechallenge. The fast and spontaneous regression of clinical symptoms is usual after stopping the suspected drug. Apart from these chronological aspects, no specific clinical or biological parameters are pathognomonic. CSF analysis usually shows pleiocytosis. The proteinorachia is increased while glycorachia remains normal. Underlying pathologies can stimulate the occurrence of DIAM. Thus, systemic lupus erythematosus appears to promote DIAM during NSAID therapy, especially ibuprofen-based one. Similarly, some patients with chronic migraine are prone to intravenous immunoglobulin-induced aseptic meningitis. DIAM will be mainly evoked on chronological criteria such as rapid occurrence after initiation, rapid regression after discontinuation, and recurrence after rechallenge of the suspected drug. When occurring, positive rechallenge may be very useful in the absence of initial diagnosis. Finally, DIAM remains a diagnosis of elimination. It should be suggested only after all infectious causes have been ruled out.

show abstract

“…Since the anti-TNF agents cannot cross the blood-brain barrier, the drugrelated direct toxic effect is not considered. 4 It may be due to a delayed hypersensitivity reaction or peripheral inhibition of TNF alpha which may lead to upregulation of proinflammatory pathways in the brain.…”

mentioning

confidence: 99%

A case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related

Akça¹,

Sokmen²,

Bolek³

et al. 2021

Turk J Pediatr

View full text Add to dashboard Cite

Background. The adverse effects of tumor necrosis factor alpha inhibitors (TNFi) are well characterized but rare adverse events are increasing day by day. Case.We presented an 18-year-old girl with rheumatoid factor positive polyarticular juvenile idiopathic arthritis (JIA) who developed fever, headache, and nausea after the second dose of adalimumab. In addition to her suspicious complaints for meningitis, she had bilateral papilledema and partial abducens nerve palsy. Leptomeningeal contrast enhancement was noted in magnetic resonance imaging (MRI) of the brain. Brain MRI venography was normal. The cerebrospinal fluid (CSF) opening pressure was high but CSF analysis was normal. She was diagnosed with non-infectious subacute meningitis. Since brain biopsy was not performed, no definite distinction could be made between TNFi related aseptic meningitis or cerebral involvement of JIA. Due to the onset of neurological complaints after initiation of adalimumab treatment and rare cerebral involvement in JIA, the drug-associated aseptic meningitis was likely to be responsible in our patient. Adalimumab was discontinued and methylprednisolone followed by methotrexate treatment were initiated. Her symptoms resolved and control brain MRI was normal. Conclusion.Pediatric rheumatologists should be aware of this potentially severe side effect of anti-TNF treatment.

show abstract

First Case Report of Aseptic Meningitis Induced by Adalimumab Administered for Treatment of Chronic Plaque Psoriasis

Abstract: Secuenciación del exoma. Secuenciación de nueva generación. Janus quinasa 3. Inmunodeficiencia primaria. Inmunodeficiencia combinada severa.

Cited by 6 publications

References 0 publications

Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease

Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease

Drug‐induced aseptic meningitis: a mini‐review

A case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related

Contact Info

Product

Resources

About